Press Releases

 Filter by Provider

Landmark results from the DeLLphi-305 Phase III trial showed IMFINZI® (durvalumab) plus Amgen’s tarlatamab-dlle demonstrated a statistically significant and highly clinically meaningful improvement in the primary endpoint of overall survival (OS) and in the key secondary endpoint of progression-free survival (PFS) versus IMFINZI alone as a 1st-line maintenance treatment. The trial included patients with extensive-stage small cell lung cancer (ES-SCLC) who had not progressed following standard induction treatment with IMFINZI plus platinum chemotherapy (investigator’s choice of carboplatin or cisplatin) and etoposide.

Stewards Investment Capital, BioVie, FreeCast and American Fusion Headline a Four-Region Broadcast Across the U.S., Latin America, MENA and Southeast Asia

Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV) demonstrated statistically significant and clinically meaningful improvements in the primary endpoint of event-free survival (EFS) and key secondary endpoint of overall survival (OS) in patients with muscle-invasive bladder cancer (MIBC) versus standard of care. Patients were ineligible for or had refused cisplatin-based chemotherapy. Patients in the comparator arm had a radical cystectomy (surgery to remove the bladder) with or without approved adjuvant treatment.

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Harte Hanks, Inc. (NASDAQ: HHS) to Star Equity Holdings, Inc. Under the terms of the proposed transaction, Harte Hanks shareholders may elect to receive either (1) $5.00 in cash for each Harte Hanks share, or (2) 0.50 shares of Star Equity’s publicly traded 10% Series A Cumulative Perpetual Preferred Stock for each Harte Hanks share.

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of GoPro, Inc. (NASDAQ: GPRO) to Starman Optical, Inc. for $1.14 per share, subject to potential adjustment based on GoPro’s net working capital at closing.

Breast cancer screening has become more accessible and sophisticated, but the process doesn't end with a mammogram. When imaging reveals an abnormality—a mass, calcifications, or architectural distortion—the next step often involves obtaining a tissue sample to determine whether the finding is benign or malignant. This diagnostic phase can be unsettling,…

The landscape of breast cancer treatment has transformed dramatically over the past two decades, but the single most powerful tool in improving survival remains unchanged: finding cancer early. While medical advances have produced better therapies and surgical techniques, detection technology has evolved in ways that allow physicians to identify suspicious…

When someone receives a cancer diagnosis, conversations with doctors naturally focus on tumors, staging, and treatment protocols. Yet beneath these headline concerns lies a network of blood vessels that plays a surprisingly decisive role in how well treatments work and how quickly patients recover. The vascular system—the highways and byways…

Adrenal tumors represent a particularly challenging category of cancer because these small glands sitting atop the kidneys control critical hormone production. When cancer develops in the adrenal cortex or medulla, patients face not only the direct threat of malignancy but also the cascading effects of hormonal imbalances that can affect…

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Innventure (INV) To Contact Him Directly To Discuss Their Options

If you purchased or acquired Flotek securities between August 3, 2026 and August 17, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In XTI (XTIA) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hyliion (HYLN) To Contact Him Directly To Discuss Their Options

Summary: Founders in Focus: Inside the Journeys & Decisions of Visionary Entrepreneurs, the third book in TJ Avazona's Founders in Focus series, has reached #1 in three Amazon categories: Shopping & Commerce Reference, Global Marketing, and Commerce. The collection features candid accounts from twelve entrepreneurs about the risks, mistakes and difficult decisions behind their businesses.

Renowned Review, The Performing Artist Issue 2, and fine-art book Life of the Day mark three new KL Publishing Group releases under Executive Editor Kaylene Peo

Managing household repairs can quickly become overwhelming and costly. Whether a refrigerator stops cooling without warning or a central air conditioning unit shuts down during a mid-summer heatwave, home repairs frequently arrive unannounced. That is where home warranty providers come in, offering service contracts designed to buffer household budgets from unexpected equipment breakdowns.

Los Angeles - October 24, 2026 - Everyone has that perfect little corner of the home where a good floor lamp and an anticipated book lead to a wonderful evening. The trick is that the future needs to complement the room, giving a place to settle, relax, and feel supported, no matter the activity. That is exactly what the EMIAH M7 power recliner provides for everyday users.

CAMBRIDGE, Mass., Oct. 24, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced updated safety and efficacy data for zolucatetide, the first and only direct inhibitor of the β-catenin:TCF interaction, in patients with desmoid tumors. The data were presented today in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27, 2026, in Madrid, Spain.The updated results, based on a June 22, 2026, data cutoff, include data from both the dose escalation and dose optimization portions of the ongoing Phase 1/2 trial and reinforce the strong efficacy and favorable safety and tolerability profile observed with zolucatetide. Among response-evaluable patients who began treatment at a starting dose of ≥450 mg, zolucatetide demonstrated an objective response rate (ORR) of 72.2% (13/18) in a 32-week landmark analysis. A disease control rate (DCR) of 100% was observed across all 46 response-evaluable patients who received a starting dose of ≥450 mg, with no disease progression.Data from a three-arm randomized dose optimization trial supported selection of a 450 mg weekly induction regimen administered for four cycles, followed by 300 mg every two weeks for long-term maintenance. Following productive end-of-Phase 2 discussions, Parabilis has reached alignment with the U.S. Food and Drug Administration (FDA) on the selected dose and regimen, on the use of a placebo-controlled study design, and on progression-free survival (PFS) as the primary endpoint for registrational development. Parabilis plans to initiate the randomized, double-blind PEDESTAL Phase 3 trial (Phase 3 Evaluation of DESmoid Tumor Activity with zoLucatetide) in the first half of 2027, with topline results anticipated in 2029. “Desmoid tumors are chronic and life-altering for patients, often affecting people at a young age, and patients need treatments that can deliver rapid, deep and durable tumor responses with a tolerability profile suited for long-term treatment,” said Mathai Mammen, M.D., Ph.D., Chairman, CEO and President of Parabilis Medicines. “We designed zolucatetide to directly inhibit β-catenin:TCF, a historically undruggable target at the heart of the biology driving these tumors. The depth and consistency of responses we are seeing, together with the favorable safety and tolerability profile observed to date, reinforce our conviction that zolucatetide has the potential to deliver a truly differentiated medicine and meaningfully expand the number of patients who can benefit from treatment. We are very pleased with the clarity of the FDA’s feedback on our registrational development strategy, and with our Phase 3 regimen selected, we are moving with urgency to bring this medicine to patients.”Updated Phase 1/2 Results As of the June 22, 2026, data cutoff, 76 patients with desmoid tumors had been enrolled and treated across all dose levels in the dose escalation and dose optimization portions of the trial. Median age was 37 years (range 19–80), and 69.7% of patients were female. The population included both patients who had previously been treated with and failed gamma-secretase inhibitors (GSIs) and patients naive to GSIs.

New late-breaking data to be presented today by the Australian and New Zealand Urogenital and Prostate (ANZUP) Clinical Trials Group at the European Society for Medical Oncology (ESMO) Congress 2026 will show that adding Bayer’s androgen receptor inhibitor (ARi), NUBEQA® (darolutamide), to standard-of-care androgen deprivation therapy (ADT) and locoregional radiation therapy (RT), improves metastasis-free survival based on conventional imaging (MFS-CI) in prostate cancer patients with high risk of recurrence compared to placebo. These data will be presented at Presidential Symposium I at the ESMO Congress 2026 (LBA4, Saturday, October 24, at 16:30 CEST/10:30 am ET).

Semtech Corporation (Nasdaq: SMTC), a leading provider of high-performance semiconductors powering AI data center networking and intelligent, connected Internet of Things (“IoT”) devices worldwide, is adding new resilient communications building blocks to its AirLink® 5G Networking Solutions. Semtech will demonstrate the new capabilities in booth #2964 at the International Association of Chiefs of Police (IACP) conference in Orlando, Fla.

The continuous expansion of decentralized finance, digital currencies, and distributed ledger protocols has introduced unprecedented challenges regarding transaction tracing and transactional clarity. As institutional and private capital flows into digital asset ecosystems, the structural opacity of decentralized networks and the irreversibility of on-chain transfers have heightened the necessity for rigorous forensic methodologies. Within this evolving operational landscape, ML-Detect.com has positioned its capabilities toward demystifying complex distributed ledger movements through structured, objective investigative processes. The organization addresses an increasingly critical gap in market infrastructure, where both enterprises and individual market participants require methodical assistance in understanding fund flows, identifying points of transaction divergence, and establishing verifiable audit trails across public cryptographic networks.

As the adoption of distributed digital assets matures across global markets, the velocity and technical complexity of on-chain activity have introduced significant operational challenges for market participants and financial infrastructure. The decentralized architecture of public ledgers, while offering distinct settlement efficiencies, has also facilitated sophisticated methods of asset diversion, unauthorized transfers, and financial fraud. In response to this shifting operational environment, Euro trace has broadened its analytical capabilities, offering structured blockchain tracing and digital forensic investigation services designed to bring evidential clarity to complex transaction histories and disputed asset movements.

VOKA 3D Anatomy & Pathology app surpasses 1 million registrations worldwide, offering 1,100+ interactive 3D models of human anatomy and pathology.

A controlled room can reduce certain contamination risks, but it does not by itself make a molded part suitable for every use. Buyers should identify which contaminants matter, where they can enter, and what evidence demonstrates control. Resin handling, mold maintenance, operators, packaging, and transport all affect the component.

NEW YORK, Oct. 24, 2026 (GLOBE NEWSWIRE) --

Applying for a same-day loan usually happens under pressure. You’re dealing with an urgent expense, time is short, and every lender’s website seems to promise the same thing: fast approval, quick cash, and no hassle. It’s easy to assume they’re all alike.

Liberty Home informeert Nederlandse patiënten over residentiële verslavingszorg in Kaapstad. Zorgvuldige intake, medische begeleiding, behandeltaal, kosten en nazorg vormen belangrijke aandachtspunten bij de keuze voor behandeling in Zuid-Afrika.AMSTERDAM, NL — October 24, 2026 — Liberty Home belicht verslavingszorg in Kaapstad voor Nederlandse patiëntenKAAPSTAD, Zuid-Afrika - Liberty Home, een aanbieder van…

Anti-tangle brush roll, 1.2-litre dust cup and a battery that clicks out, backed by a 60-day home trial and a five-year warranty

Presentation software used to start with a blank slide. You chose a layout, added a title, and built the deck one page at a time. That process could be slow even when the ideas were already clear.

NEW YORK, Oct. 24, 2026 (GLOBE NEWSWIRE) --

Receiver-in-canal design streams phone calls and music to both ears, fits smaller ear canals and includes a 90-day home trial

NEW YORK, Oct. 24, 2026 (GLOBE NEWSWIRE) --

Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with INCB161734, Incyte’s investigational, potent and selective KRAS G12D inhibitor, and standard-of-care chemotherapy as a first-line treatment for patients with metastatic colorectal cancer harboring a KRAS G12D mutation, an area with substantial unmet medical need.

Incyte (Nasdaq:INCY) and Genmab A/S (Nasdaq:GMAB) today announced a clinical trial collaboration to evaluate INCB161734, Incyte’s investigational, potent and selective KRAS G12D inhibitor, in combination with petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), and standard-of-care chemotherapy as a first-line treatment for patients with metastatic colorectal cancer harboring KRAS G12D mutation, an area with substantial unmet medical need.

Data presented at the 2026 Congress of the European Society for Medical Oncology

Finding a public meeting record should be simple. A resident may want to confirm a vote, check what was approved, download the official minutes, or compare the written record with the meeting video. That is why meeting-management software matters: it connects agendas, supporting documents, meeting actions, minutes, approvals, and public access into one workflow.

NEW YORK, Oct. 24, 2026 (GLOBE NEWSWIRE) --

MUSCAT, Oman, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Asyad Group will host the Muscat Maritime Resilience Forum 2026 on 27–28 October in partnership with the Foreign Ministry of Oman, the Ministry of Transport, Communications and Information Technology, and Oman Investment Authority. The partnership reflects a coordinated national effort to strengthen Oman’s role in international discussions on the future of trade and global maritime routes.

AppLovin has been sued for securities fraud after its stock plummeted 20% because AppLovin allegedly misrepresented the strength, viability, and development of its AI-based business model and products.

NEW YORK, Oct. 24, 2026 (GLOBE NEWSWIRE) --

Upgrade your namecard to a dynamic digital namecard — free forever. Digital Namecard, Dynamic Card, Digital Card and Business Card by AddMy.co.

BFA Law is investigating the announced $7.75 per share merger in which a coalition led by GTRC LLC and including Elliott Investment Management L.P. is set to acquire CCC Intelligent Solutions, Inc.; current shareholders are notified to contact the firm.

Ensign has been sued for securities fraud after its stock price fell following reports alleging that the company concealed patient neglect, understaffing, manipulated quality and staffing data, improper billing, and an administrator-license rental scheme.

Fluence has been sued for securities fraud after its stock plummeted 35% because Fluence allegedly misrepresented the status of its manufacturing operations and ability to achieve its revenue and EBITDA guidance.

BFA Law is investigating whether Six Flags Entertainment Corporation committed securities fraud relating to statements about its focus on safety, maintenance, and ride reliability.

Gildan has been sued for securities fraud after its stock plummeted 18.75% because Gildan allegedly used channel stuffing to create the appearance of revenue and misrepresented its financial results and effectiveness of internal controls.

Alphabet has been sued for securities fraud after its stock price fell 4% because Alphabet allegedly misrepresented the progress of development of its Gemini 3.5 Pro AI model.